Table 3

Characteristics of studies comparing pregnancy outcome in women with HbSC against women with no SCD

CountryGNI $ (year)Duration of studyHbSC women, N (N pregnancies)No SCD, N (N pregnancies)Transfusion detailsQuality of reporting (NOS) of 9
Total N    279 (331) 1074 (1231)   
First author and year of publication        
 Howard 199517  United Kingdom 37 340 (2012) 1991-1993 33 (33) 100 (100) 21.2% HbSC transfused in 1st or 2nd trimester (prophylactic); 
 Ngo 201018  France 36 720 (2012) 1994-2004 33 (33) 128 (128) Prophylactic transfusion for all HbSC 
 Serjeant 2005* Jamaica 5120 (2012) 1973-2004 43 (95) 68 (157) 11.6% HbSC (on clinical indications) 
 Sun 200120  United States 52 610 (2012) 1980-1995 58 (58) 61 (129) 21% of HbSC (on clinical indications) vs 0% controls 
 Wilson 201223  Ghana 1910 (2012) 2007-2008 112 (112) 717 (717) No data on transfusion for study population 
CountryGNI $ (year)Duration of studyHbSC women, N (N pregnancies)No SCD, N (N pregnancies)Transfusion detailsQuality of reporting (NOS) of 9
Total N    279 (331) 1074 (1231)   
First author and year of publication        
 Howard 199517  United Kingdom 37 340 (2012) 1991-1993 33 (33) 100 (100) 21.2% HbSC transfused in 1st or 2nd trimester (prophylactic); 
 Ngo 201018  France 36 720 (2012) 1994-2004 33 (33) 128 (128) Prophylactic transfusion for all HbSC 
 Serjeant 2005* Jamaica 5120 (2012) 1973-2004 43 (95) 68 (157) 11.6% HbSC (on clinical indications) 
 Sun 200120  United States 52 610 (2012) 1980-1995 58 (58) 61 (129) 21% of HbSC (on clinical indications) vs 0% controls 
 Wilson 201223  Ghana 1910 (2012) 2007-2008 112 (112) 717 (717) No data on transfusion for study population 

All studies were historical cohort studies of pregnancy except for those marked *, which were prospective pregnancy cohort studies.

Close Modal

or Create an Account

Close Modal
Close Modal